Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Beta-Lactams : Novel Synthetic Pathways and Applications / Bimal K. Banik editor
| Beta-Lactams : Novel Synthetic Pathways and Applications / Bimal K. Banik editor |
| Pubbl/distr/stampa | Cham, : Springer, 2017 |
| Descrizione fisica | VII, 419 p. : ill. ; 24 cm |
| Disciplina |
540(Chimica generale)
547(Chimica organica) 615.1(Farmacologia. Farmaci. Farmacia) 615.19(Chimica farmaceutica. Tecnologia farmaceutica. Chimica medica) 616.9041(Microbiologia medica. Farmacoresistenza) 615.580724(Ricerca sperimentale (Sperimentazioni cliniche di farmaci)) |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNICAMPANIA-VAN0123334 |
| Cham, : Springer, 2017 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Vanvitelli | ||
| ||
Beta-Lactams : Novel Synthetic Pathways and Applications / Bimal K. Banik editor
| Beta-Lactams : Novel Synthetic Pathways and Applications / Bimal K. Banik editor |
| Pubbl/distr/stampa | Cham, : Springer, 2017 |
| Descrizione fisica | VII, 419 p. : ill. ; 24 cm |
| Disciplina |
540(Chimica generale)
547(Chimica organica) 615.1(Farmacologia. Farmaci. Farmacia) 615.19(Chimica farmaceutica. Tecnologia farmaceutica. Chimica medica) 616.9041(Microbiologia medica. Farmacoresistenza) 615.580724(Ricerca sperimentale (Sperimentazioni cliniche di farmaci)) |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNICAMPANIA-VAN00123334 |
| Cham, : Springer, 2017 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Vanvitelli | ||
| ||
Beta-Lactams : Novel Synthetic Pathways and Applications / Bimal K. Banik editor
| Beta-Lactams : Novel Synthetic Pathways and Applications / Bimal K. Banik editor |
| Edizione | [Cham : Springer, 2017] |
| Pubbl/distr/stampa | VII, 419 p., : ill. ; 24 cm |
| Descrizione fisica | Pubblicazione in formato elettronico |
| Disciplina |
540(Chimica generale)
547(Chimica organica) 615.1(Farmacologia. Farmaci. Farmacia) 615.19(Chimica farmaceutica. Tecnologia farmaceutica) 616.9041(Microbiologia medica. Farmacoresistenza) 615.580724(Ricerca sperimentale (Sperimentazioni cliniche di farmaci)) |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNICAMPANIA-SUN0123334 |
| VII, 419 p., : ill. ; 24 cm | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Vanvitelli | ||
| ||
Biosimulation in drug development / / edited by Martin Bertau, Erik Mosekilde, and Hans V. Westerhoff
| Biosimulation in drug development / / edited by Martin Bertau, Erik Mosekilde, and Hans V. Westerhoff |
| Pubbl/distr/stampa | Weinheim, Germany : , : WILEY-VCH Verlag GmbH & Co. KGaA, , 2008 |
| Descrizione fisica | 1 online resource (542 p.) |
| Disciplina | 615.580724 |
| Soggetto topico |
Drug development
Drug development - Simulation methods |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-281-94698-2
9786611946982 3-527-62267-5 3-527-62268-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Biosimulation in Drug Development; Contents; Preface; List of Contributors; Part I Introduction; 1 Simulation in Clinical Drug Development; 1.1 Introduction; 1.2 Models for Simulations; 1.3 Simulations in Clinical Drug Development: Practical Examples; 1.3.1 Predicting the Outcome of Phase I Studies of Erythropoietin Receptor Agonists; 1.3.2 Simulations for Antimicrobial Dose Selection; 1.3.3 Optimizing the Design of Phase II Dose Finding Studies; 1.3.4 Predicting the Outcome of Phase III Trials Using Phase II Data; 1.4 Conclusions; 2 Modeling of Complex Biomedical Systems; 2.1 Introduction
2.2 Pulsatile Secretion of Insulin2.3 Subcutaneous Absorption of Insulin; 2.4 Bursting Pancreatic β-Cells; 2.5 Conclusions; 3 Biosimulation of Drug Metabolism; 3.1 Introduction; 3.2 Experimental Approaches; 3.2.1 Animal Test Models; 3.2.2 Microbial Models; 3.3 The Biosimulation Approach; 3.4 Ethical Issues; 3.5 PharmBiosim - a Computer Model of Drug Metabolism in Yeast; 3.5.1 General Concept; 3.5.1.1 Chemical Abstraction; 3.5.1.2 Biological Abstraction; 3.5.2 Initial Steps - Experimental Results; 3.5.2.1 Dehalogenation (Pathways II and III); 3.5.2.2 Retro-Claisen Condensation (Pathway IV) 3.5.2.3 Ester Hydrolysis (Pathway VI)3.5.2.4 Competing Pathways and Stereoselectivity; 3.6 Computational Modeling; 3.6.1 Selection of the Modeling Software; 3.6.2 SBML-compatible Software; 3.6.2.1 Cellware; 3.6.2.2 Copasi; 3.6.2.3 Ecell; 3.6.2.4 JigCell; 3.6.2.5 JSim; 3.6.2.6 Systems Biology Workbench; 3.6.2.7 Virtual Cell; 3.6.2.8 XPPAUT; 3.6.3 CellML-compatible Software; 3.6.4 Kinetic Model; 3.6.4.1 Methods; 3.6.4.2 Model Derivation; 3.6.4.3 Results; 3.6.5 Stoichiometric Model; 3.6.5.1 Methods; 3.6.5.2 Model Derivation; 3.6.5.3 Results 3.7 Application of the Model to Predict Drug Metabolism3.8 Conclusions; Part II Simulating Cells and Tissues; 4 Correlation Between In Vitro, In Situ, and In Vivo Models; 4.1 Introduction; 4.2 Biophysical Models of Intestinal Absorption; 4.2.1 Colon; 4.2.2 Small Intestine; 4.2.3 Stomach; 4.3 Influence of Surfactants on Intestinal Permeability; 4.3.1 Absorption Experiments in Presence of Surfactants; 4.3.1.1 Colon; 4.3.1.2 Intestine; 4.3.1.3 Stomach; 4.4 Modeling and Predicting Fraction Absorbed from Permeability Values; 4.4.1 Mass Balance, Time-independent Models 4.4.2 Prediction of the Fraction of Dose Absorbed from In Vitro and In Situ Data4.4.3 Prediction from In Situ Absorption Rate Constant Determined with Closed Loop Techniques; 4.4.4 Prediction from Permeabilities Through Caco-2 Cell Lines; 4.4.5 Prediction from the PAMPA In Vitro System; 4.5 Characterization of Active Transport Parameters; 4.5.1 In Situ Parameter Estimation; 4.5.2 In Vitro-In Situ Correlation; 5 Core-Box Modeling in the Biosimulation of Drug Action; 5.1 Introduction; 5.2 Core-Box Modeling; 5.2.1 Shortcomings of Gray-Box and Minimal Modeling 5.2.1.1 Full-Scale Mechanistic Gray-Box Modeling |
| Record Nr. | UNINA-9910144228403321 |
| Weinheim, Germany : , : WILEY-VCH Verlag GmbH & Co. KGaA, , 2008 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Biosimulation in drug development / / edited by Martin Bertau, Erik Mosekilde, and Hans V. Westerhoff
| Biosimulation in drug development / / edited by Martin Bertau, Erik Mosekilde, and Hans V. Westerhoff |
| Pubbl/distr/stampa | Weinheim, Germany : , : WILEY-VCH Verlag GmbH & Co. KGaA, , 2008 |
| Descrizione fisica | 1 online resource (542 p.) |
| Disciplina | 615.580724 |
| Soggetto topico |
Drug development
Drug development - Simulation methods |
| ISBN |
1-281-94698-2
9786611946982 3-527-62267-5 3-527-62268-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Biosimulation in Drug Development; Contents; Preface; List of Contributors; Part I Introduction; 1 Simulation in Clinical Drug Development; 1.1 Introduction; 1.2 Models for Simulations; 1.3 Simulations in Clinical Drug Development: Practical Examples; 1.3.1 Predicting the Outcome of Phase I Studies of Erythropoietin Receptor Agonists; 1.3.2 Simulations for Antimicrobial Dose Selection; 1.3.3 Optimizing the Design of Phase II Dose Finding Studies; 1.3.4 Predicting the Outcome of Phase III Trials Using Phase II Data; 1.4 Conclusions; 2 Modeling of Complex Biomedical Systems; 2.1 Introduction
2.2 Pulsatile Secretion of Insulin2.3 Subcutaneous Absorption of Insulin; 2.4 Bursting Pancreatic β-Cells; 2.5 Conclusions; 3 Biosimulation of Drug Metabolism; 3.1 Introduction; 3.2 Experimental Approaches; 3.2.1 Animal Test Models; 3.2.2 Microbial Models; 3.3 The Biosimulation Approach; 3.4 Ethical Issues; 3.5 PharmBiosim - a Computer Model of Drug Metabolism in Yeast; 3.5.1 General Concept; 3.5.1.1 Chemical Abstraction; 3.5.1.2 Biological Abstraction; 3.5.2 Initial Steps - Experimental Results; 3.5.2.1 Dehalogenation (Pathways II and III); 3.5.2.2 Retro-Claisen Condensation (Pathway IV) 3.5.2.3 Ester Hydrolysis (Pathway VI)3.5.2.4 Competing Pathways and Stereoselectivity; 3.6 Computational Modeling; 3.6.1 Selection of the Modeling Software; 3.6.2 SBML-compatible Software; 3.6.2.1 Cellware; 3.6.2.2 Copasi; 3.6.2.3 Ecell; 3.6.2.4 JigCell; 3.6.2.5 JSim; 3.6.2.6 Systems Biology Workbench; 3.6.2.7 Virtual Cell; 3.6.2.8 XPPAUT; 3.6.3 CellML-compatible Software; 3.6.4 Kinetic Model; 3.6.4.1 Methods; 3.6.4.2 Model Derivation; 3.6.4.3 Results; 3.6.5 Stoichiometric Model; 3.6.5.1 Methods; 3.6.5.2 Model Derivation; 3.6.5.3 Results 3.7 Application of the Model to Predict Drug Metabolism3.8 Conclusions; Part II Simulating Cells and Tissues; 4 Correlation Between In Vitro, In Situ, and In Vivo Models; 4.1 Introduction; 4.2 Biophysical Models of Intestinal Absorption; 4.2.1 Colon; 4.2.2 Small Intestine; 4.2.3 Stomach; 4.3 Influence of Surfactants on Intestinal Permeability; 4.3.1 Absorption Experiments in Presence of Surfactants; 4.3.1.1 Colon; 4.3.1.2 Intestine; 4.3.1.3 Stomach; 4.4 Modeling and Predicting Fraction Absorbed from Permeability Values; 4.4.1 Mass Balance, Time-independent Models 4.4.2 Prediction of the Fraction of Dose Absorbed from In Vitro and In Situ Data4.4.3 Prediction from In Situ Absorption Rate Constant Determined with Closed Loop Techniques; 4.4.4 Prediction from Permeabilities Through Caco-2 Cell Lines; 4.4.5 Prediction from the PAMPA In Vitro System; 4.5 Characterization of Active Transport Parameters; 4.5.1 In Situ Parameter Estimation; 4.5.2 In Vitro-In Situ Correlation; 5 Core-Box Modeling in the Biosimulation of Drug Action; 5.1 Introduction; 5.2 Core-Box Modeling; 5.2.1 Shortcomings of Gray-Box and Minimal Modeling 5.2.1.1 Full-Scale Mechanistic Gray-Box Modeling |
| Record Nr. | UNINA-9910830717703321 |
| Weinheim, Germany : , : WILEY-VCH Verlag GmbH & Co. KGaA, , 2008 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Clinical pharmacology : advances and applications
| Clinical pharmacology : advances and applications |
| Pubbl/distr/stampa | [Auckland, NZ], : Dove Medical Press |
| Descrizione fisica | 1 online resource |
| Disciplina | 615.580724 |
| Soggetto topico |
Clinical pharmacology
Pharmacology, Clinical Pharmacology |
| Soggetto genere / forma | Periodicals. |
| Soggetto non controllato | Pharmacy, Therapeutics, & Pharmacology |
| ISSN | 1179-1438 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Record Nr. | UNISA-996200824303316 |
| [Auckland, NZ], : Dove Medical Press | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
Clinical pharmacology : advances and applications
| Clinical pharmacology : advances and applications |
| Pubbl/distr/stampa | [Auckland, NZ], : Dove Medical Press |
| Descrizione fisica | 1 online resource |
| Disciplina | 615.580724 |
| Soggetto topico |
Clinical pharmacology
Pharmacology, Clinical Pharmacology |
| Soggetto genere / forma |
Periodical
Periodicals. |
| ISSN | 1179-1438 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910139253303321 |
| [Auckland, NZ], : Dove Medical Press | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Clinical trials handbook [[electronic resource] /] / edited by Shayne Cox Gad
| Clinical trials handbook [[electronic resource] /] / edited by Shayne Cox Gad |
| Pubbl/distr/stampa | Hoboken, NJ, : Wiley, c2009 |
| Descrizione fisica | 1 online resource (1247 p.) |
| Disciplina |
615.1
615.580724 615/.1 |
| Altri autori (Persone) | GadShayne C. <1948-> |
| Collana | Pharmaceutical Development Series |
| Soggetto topico |
Drugs - Testing
Clinical trials |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-282-36844-3
9786612368448 0-470-46636-7 0-470-46635-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Clinical Trials Handbook; Contents; Preface; Contributors; 1 Introduction to Clinical Trials; 2 Regulatory Requirements for Investigational New Drug; 3 Preclinical Assessment of Safety in Human Subjects; 4 Predicting Human Adverse Drug Reactions from Nonclinical Safety Studies; 5.1 History of Clinical Trial Development and the Pharmaceutical Industry; 5.2 Adaptive Research; 6 Organization and Planning; 7 Process of Data Management; 8 Clinical Trials Data Management; 9.1 Clinical Trials and the Food and Drug Administration; 9.2 Phase I Clinical Trials; 9.3 Phase II Clinical Trials
9.4 Designing and Conducting Phase III Studies9.5 Phase IV: Postmarketing Trials; 9.6 Phase IV and Postmarketing Clinical Trials; 9.7 Regulatory Approval; 9.8 New Paradigm for Analyzing Adverse Drug Events; 10.1 Clinical Trials in Interventional Cardiology: Focus on XIENCE Drug-Eluting Stent; 10.2 Clinical Trials Involving Oral Diseases; 10.3 Dermatology Clinical Trials; 10.4 Emergency Clinical Trials; 10.5 Gastroenterology; 10.6 Gynecology Randomized Control Trials; 10.7 Special Population Studies (Healthy Patient Studies); 10.8 Musculoskeletal Disorders; 10.9 Oncology 10.10 Pharmacological Treatment Options for Nonexudative and Exudative Age-Related Macular Degeneration10.11 Paediatrics; 10.12 Clinical Trials in Dementia; 10.13 Clinical Trials in Urology; 10.14 Clinical Trials on Cognitive Drugs; 10.15 Bridging Studies in Pharmaceutical Safety Assessment; 10.16 Brief History of Clinical Trials on Viral Vaccines; 11 Methods of Randomization; 12 Randomized Controlled Trials; 13 Cross-Over Designs; 14.1 Biomarkers; 14.2 Biomarkers in Clinical Drug Development: Parallel Analysis of Alzheimer Disease and Multiple Sclerosis; 15 Review Boards 16 Size of Clinical Trials17 Blinding and Placebo; 18 Pharmacology; 19 Modeling and Simulation in Clinical Drug Development; 20 Monitoring; 21 Inference Following Sequential Clinical Trials; 22 Statistical Methods for Analysis of Clinical Trials; 23 Explanatory and Pragmatic Clinical Trials; 24.1 Ethics of Clinical Research in Durg Trials; 24.2 Ethical Issues in Clinical Research; 25 Regulations; 26 Future Challenges in Design and Ethics of Clinical Trials; 27 Proof-of-Principle/Proof-of-Concept Trials in Drug Development; Index |
| Record Nr. | UNINA-9910455072803321 |
| Hoboken, NJ, : Wiley, c2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Clinical trials handbook [[electronic resource] /] / edited by Shayne Cox Gad
| Clinical trials handbook [[electronic resource] /] / edited by Shayne Cox Gad |
| Pubbl/distr/stampa | Hoboken, NJ, : Wiley, c2009 |
| Descrizione fisica | 1 online resource (1247 p.) |
| Disciplina |
615.1
615.580724 615/.1 |
| Altri autori (Persone) | GadShayne C. <1948-> |
| Collana | Pharmaceutical Development Series |
| Soggetto topico |
Drugs - Testing
Clinical trials |
| ISBN |
1-282-36844-3
9786612368448 0-470-46636-7 0-470-46635-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Clinical Trials Handbook; Contents; Preface; Contributors; 1 Introduction to Clinical Trials; 2 Regulatory Requirements for Investigational New Drug; 3 Preclinical Assessment of Safety in Human Subjects; 4 Predicting Human Adverse Drug Reactions from Nonclinical Safety Studies; 5.1 History of Clinical Trial Development and the Pharmaceutical Industry; 5.2 Adaptive Research; 6 Organization and Planning; 7 Process of Data Management; 8 Clinical Trials Data Management; 9.1 Clinical Trials and the Food and Drug Administration; 9.2 Phase I Clinical Trials; 9.3 Phase II Clinical Trials
9.4 Designing and Conducting Phase III Studies9.5 Phase IV: Postmarketing Trials; 9.6 Phase IV and Postmarketing Clinical Trials; 9.7 Regulatory Approval; 9.8 New Paradigm for Analyzing Adverse Drug Events; 10.1 Clinical Trials in Interventional Cardiology: Focus on XIENCE Drug-Eluting Stent; 10.2 Clinical Trials Involving Oral Diseases; 10.3 Dermatology Clinical Trials; 10.4 Emergency Clinical Trials; 10.5 Gastroenterology; 10.6 Gynecology Randomized Control Trials; 10.7 Special Population Studies (Healthy Patient Studies); 10.8 Musculoskeletal Disorders; 10.9 Oncology 10.10 Pharmacological Treatment Options for Nonexudative and Exudative Age-Related Macular Degeneration10.11 Paediatrics; 10.12 Clinical Trials in Dementia; 10.13 Clinical Trials in Urology; 10.14 Clinical Trials on Cognitive Drugs; 10.15 Bridging Studies in Pharmaceutical Safety Assessment; 10.16 Brief History of Clinical Trials on Viral Vaccines; 11 Methods of Randomization; 12 Randomized Controlled Trials; 13 Cross-Over Designs; 14.1 Biomarkers; 14.2 Biomarkers in Clinical Drug Development: Parallel Analysis of Alzheimer Disease and Multiple Sclerosis; 15 Review Boards 16 Size of Clinical Trials17 Blinding and Placebo; 18 Pharmacology; 19 Modeling and Simulation in Clinical Drug Development; 20 Monitoring; 21 Inference Following Sequential Clinical Trials; 22 Statistical Methods for Analysis of Clinical Trials; 23 Explanatory and Pragmatic Clinical Trials; 24.1 Ethics of Clinical Research in Durg Trials; 24.2 Ethical Issues in Clinical Research; 25 Regulations; 26 Future Challenges in Design and Ethics of Clinical Trials; 27 Proof-of-Principle/Proof-of-Concept Trials in Drug Development; Index |
| Record Nr. | UNINA-9910778685003321 |
| Hoboken, NJ, : Wiley, c2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
The Cox Model and Its Applications / / by Mikhail Nikulin, Hong-Dar Isaac Wu
| The Cox Model and Its Applications / / by Mikhail Nikulin, Hong-Dar Isaac Wu |
| Autore | Nikulin Mikhail |
| Edizione | [1st ed. 2016.] |
| Pubbl/distr/stampa | Berlin, Heidelberg : , : Springer Berlin Heidelberg : , : Imprint : Springer, , 2016 |
| Descrizione fisica | 1 online resource (131 p.) |
| Disciplina | 615.580724 |
| Collana | SpringerBriefs in Statistics |
| Soggetto topico |
Statistics
Biostatistics Epidemiology Statistical Theory and Methods Statistics for Life Sciences, Medicine, Health Sciences |
| ISBN | 3-662-49332-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Introduction: Several Classical Data Examples for Survival Analysis -- Elements of Survival Analysis -- The Cox Proportional Hazards Model -- The AFT, GPH, LT, Frailty, and GLPH Models -- Cross-effect Models of Survival Functions -- The Simple Cross-effect Model -- Goodness-of-Fit for the Cox Model -- Remarks on Computations in Parametric and Semiparametric Estimation -- Cox Model for Degradation and Failure Time Data -- References -- Index. |
| Record Nr. | UNINA-9910254075403321 |
Nikulin Mikhail
|
||
| Berlin, Heidelberg : , : Springer Berlin Heidelberg : , : Imprint : Springer, , 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
